| __timestamp | HUTCHMED (China) Limited | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 33472000 | 94231000 |
| Thursday, January 1, 2015 | 47368000 | 146394000 |
| Friday, January 1, 2016 | 66871000 | 188272000 |
| Sunday, January 1, 2017 | 50675000 | 166707000 |
| Monday, January 1, 2018 | 78821000 | 401843000 |
| Tuesday, January 1, 2019 | 91944000 | 560909000 |
| Wednesday, January 1, 2020 | 111234000 | 722343000 |
| Friday, January 1, 2021 | 207447000 | 771182000 |
| Saturday, January 1, 2022 | 267587000 | 877090000 |
| Sunday, January 1, 2023 | 303055000 | 877387000 |
In pursuit of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood that fuels innovation and growth. Over the past decade, Sarepta Therapeutics, Inc. and HUTCHMED (China) Limited have emerged as key players, each with a unique trajectory in their R&D investments. From 2014 to 2023, Sarepta Therapeutics has consistently outpaced HUTCHMED, with R&D expenses peaking at nearly 880% of their 2014 levels by 2023. This reflects a robust commitment to advancing their therapeutic pipeline. Meanwhile, HUTCHMED has shown a remarkable growth trajectory, with R&D spending increasing by approximately 900% over the same period. This surge underscores their strategic focus on expanding their research capabilities. As these companies continue to invest heavily in R&D, they are poised to drive significant advancements in the biotech sector, promising a future rich with innovation and discovery.
Analyzing R&D Budgets: Merck & Co., Inc. vs HUTCHMED (China) Limited
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and HUTCHMED (China) Limited
Research and Development Investment: BeiGene, Ltd. vs HUTCHMED (China) Limited
Research and Development Expenses Breakdown: Sarepta Therapeutics, Inc. vs Lantheus Holdings, Inc.
Research and Development: Comparing Key Metrics for Sarepta Therapeutics, Inc. and Veracyte, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and Protagonist Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.: Strategic Focus on R&D Spending
Exelixis, Inc. vs HUTCHMED (China) Limited: Strategic Focus on R&D Spending
Research and Development Investment: Jazz Pharmaceuticals plc vs HUTCHMED (China) Limited
R&D Insights: How Axsome Therapeutics, Inc. and HUTCHMED (China) Limited Allocate Funds
Comparing Innovation Spending: ADMA Biologics, Inc. and HUTCHMED (China) Limited
Research and Development Expenses Breakdown: HUTCHMED (China) Limited vs MiMedx Group, Inc.